FDA approves a new drug for arthritis

Article Abstract:

Genetically engineered Enbrel, made by American Home Products' Immunex Corp., has received approval for marketing to doctors for use as a treatment, but not cure, with patients suffering from severe arthritis. Clinical trials were reportedly impressive as are case histories. The apparent lack of side effects is one reason. The new treatment costs about $220 per week and involves self-injection by the patient. The medical community and patients alike anxiously await news of the drug's long-term side effects. Enbrel could help about 2.5 million Americans with the severe form of arthritis that this drug is meant to treat.

Product introduction, Health aspects, Drugs, Arthritis, Immunex Corp., AHP, IMNX, Wyeth

---

Monsanto's arthritis drug, Celebrex, shows strong sales in its first week

Article Abstract:

Monsanto's Celebrex for arthritis pain is selling at a 'mind-boggling' rate its first week on the market, 9,923 prescriptions. Only Viagra did better. Even though Pfizer is a co-marketing partner, neither firms' sales teams have really begun selling. The main benefit of the new drug is not its ability to relieve pain any better but that it doesn't upset the stomach or cause bleeding ulcers. Some doctors caution about possible long-term side effects that are still not known.

Comment:

Patients and doctors anxious for new drug

Sales & consumption, Supply and demand, Statistics, Monsanto Co., MTC, Anti-inflammatory drugs

---

Similar abstracts:

• Abstracts: Abbott acquires co-marketing rights to arthritis drug. Monsanto arthritis-pain drug, Celebrex, surpasses Viagra's early sales success
• Abstracts: Ford to sponsor Time's special reports on envirnoment, in unusual agreement. List of 1998 advertising blunders is played down by outfits named
• Abstracts: Tricon is primed to serve up a fast-food turnaround; operating earnings to show a big jump for year following PepsiCo spinoff
• Abstracts: Self magazine's editor to quit in October. Newsweek names Mark Whitaker editor to succeed Maynard Parker

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.